SERMs: Current status and future trends

Karla C. Morello, Gregory T. Wurz, Michael W. DeGregorio

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Selective estrogen receptor modulators, or SERMs, are a class of compounds that can act as estrogen receptor (ER) agonists in some tissues while acting as ER antagonists in others. SERMs are being evaluated and used to treat and prevent such diseases as breast cancer, osteoporosis, and cardiovascular disease. Currently, three primary SERMs are used clinically, which include tamoxifen, toremifene (triphenylethylenes), and raloxifene (a benzothiophene). Tamoxifen and toremifene have beneficial effects on bone and serum lipids, and are currently used to treat breast cancer. Both have stimulatory effects on the uterus. Raloxifene, indicated for the treatment and prevention of osteoporosis, also has beneficial effects on bone and serum lipids, but does not stimulate the uterus. All three are associated with venous thromboembolism and hot flashes. New SERMs to treat and prevent breast cancer, osteoporosis, and cardiovascular disease are undergoing clinical development, including idoxifene, droloxifene, ospemifene, lasofoxifene, arzoxifene, and MDL 103,323.

Original languageEnglish (US)
Pages (from-to)63-76
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume43
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Selective Estrogen Receptor Modulators
Toremifene
Osteoporosis
Tamoxifen
Breast Neoplasms
LY 353381
Uterus
Cardiovascular Diseases
Hot Flashes
Lipids
Bone and Bones
Venous Thromboembolism
Serum
Estrogens

Keywords

  • Breast cancer
  • Cardiovascular disease
  • Hormone replacement therapy
  • Osteoporosis
  • SERM

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

SERMs : Current status and future trends. / Morello, Karla C.; Wurz, Gregory T.; DeGregorio, Michael W.

In: Critical Reviews in Oncology/Hematology, Vol. 43, No. 1, 2002, p. 63-76.

Research output: Contribution to journalArticle

Morello, Karla C. ; Wurz, Gregory T. ; DeGregorio, Michael W. / SERMs : Current status and future trends. In: Critical Reviews in Oncology/Hematology. 2002 ; Vol. 43, No. 1. pp. 63-76.
@article{0352068dd43f4157ab34d3d8a83730bd,
title = "SERMs: Current status and future trends",
abstract = "Selective estrogen receptor modulators, or SERMs, are a class of compounds that can act as estrogen receptor (ER) agonists in some tissues while acting as ER antagonists in others. SERMs are being evaluated and used to treat and prevent such diseases as breast cancer, osteoporosis, and cardiovascular disease. Currently, three primary SERMs are used clinically, which include tamoxifen, toremifene (triphenylethylenes), and raloxifene (a benzothiophene). Tamoxifen and toremifene have beneficial effects on bone and serum lipids, and are currently used to treat breast cancer. Both have stimulatory effects on the uterus. Raloxifene, indicated for the treatment and prevention of osteoporosis, also has beneficial effects on bone and serum lipids, but does not stimulate the uterus. All three are associated with venous thromboembolism and hot flashes. New SERMs to treat and prevent breast cancer, osteoporosis, and cardiovascular disease are undergoing clinical development, including idoxifene, droloxifene, ospemifene, lasofoxifene, arzoxifene, and MDL 103,323.",
keywords = "Breast cancer, Cardiovascular disease, Hormone replacement therapy, Osteoporosis, SERM",
author = "Morello, {Karla C.} and Wurz, {Gregory T.} and DeGregorio, {Michael W.}",
year = "2002",
doi = "10.1016/S1040-8428(02)00022-7",
language = "English (US)",
volume = "43",
pages = "63--76",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - SERMs

T2 - Current status and future trends

AU - Morello, Karla C.

AU - Wurz, Gregory T.

AU - DeGregorio, Michael W.

PY - 2002

Y1 - 2002

N2 - Selective estrogen receptor modulators, or SERMs, are a class of compounds that can act as estrogen receptor (ER) agonists in some tissues while acting as ER antagonists in others. SERMs are being evaluated and used to treat and prevent such diseases as breast cancer, osteoporosis, and cardiovascular disease. Currently, three primary SERMs are used clinically, which include tamoxifen, toremifene (triphenylethylenes), and raloxifene (a benzothiophene). Tamoxifen and toremifene have beneficial effects on bone and serum lipids, and are currently used to treat breast cancer. Both have stimulatory effects on the uterus. Raloxifene, indicated for the treatment and prevention of osteoporosis, also has beneficial effects on bone and serum lipids, but does not stimulate the uterus. All three are associated with venous thromboembolism and hot flashes. New SERMs to treat and prevent breast cancer, osteoporosis, and cardiovascular disease are undergoing clinical development, including idoxifene, droloxifene, ospemifene, lasofoxifene, arzoxifene, and MDL 103,323.

AB - Selective estrogen receptor modulators, or SERMs, are a class of compounds that can act as estrogen receptor (ER) agonists in some tissues while acting as ER antagonists in others. SERMs are being evaluated and used to treat and prevent such diseases as breast cancer, osteoporosis, and cardiovascular disease. Currently, three primary SERMs are used clinically, which include tamoxifen, toremifene (triphenylethylenes), and raloxifene (a benzothiophene). Tamoxifen and toremifene have beneficial effects on bone and serum lipids, and are currently used to treat breast cancer. Both have stimulatory effects on the uterus. Raloxifene, indicated for the treatment and prevention of osteoporosis, also has beneficial effects on bone and serum lipids, but does not stimulate the uterus. All three are associated with venous thromboembolism and hot flashes. New SERMs to treat and prevent breast cancer, osteoporosis, and cardiovascular disease are undergoing clinical development, including idoxifene, droloxifene, ospemifene, lasofoxifene, arzoxifene, and MDL 103,323.

KW - Breast cancer

KW - Cardiovascular disease

KW - Hormone replacement therapy

KW - Osteoporosis

KW - SERM

UR - http://www.scopus.com/inward/record.url?scp=0036299286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036299286&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(02)00022-7

DO - 10.1016/S1040-8428(02)00022-7

M3 - Article

C2 - 12098608

AN - SCOPUS:0036299286

VL - 43

SP - 63

EP - 76

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -